A Feasibility Study of Octreotide Infusion During Liver Transplant.

• Status: Not yet recruiting
• Trial end date: 2023-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether an octreotide infusion during liver transplantation improves renal outcomes, intraoperative blood pressure and reduces haemorrhage and transfusion requirement.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University College, London
• Collaborator: National Institute for Health Research, United Kingdom
• Treatments: Octreotide

Criteria

Inclusion Criteria:

• Adults aged 18 years and over undergoing primary liver transplantation of a whole or partial liver graft from a cardiac or brain dead donor.

• Provision of written informed consent.

Exclusion Criteria:

• Previous solid organ transplant.

• Acute liver failure.

• Fulminant hepatic failure.

• Patients receiving a living donor liver graft.

• Patients currently admitted to ICU prior to transplantation.

• Requirement of haemodialysis or CVVHF pre-operatively.

• Known allergy or adverse reaction to octreotide.

• Pre-operative decision to use intra-operative CVVHF.

• A positive pregnancy test.